Evidence map›Paper›PMID 36305849›Full record

ArticleCancer medicine2023

Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study.

Yi-Sheng Chou, Chun-Chieh Wang, Li-Fei Hsu, Pei-Hung Chuang, Chi-Feng Cheng, Nai-Hsin Li, Chu-Chieh Chen, Chien-Liang Chen, Yun-Ju Lai, Yung-Feng Yen

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Cardio-Oncology and Breast Cancer Therapies.Current treatment options in oncology · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Targeting Breast Cancer: An Overlook on Current Strategies.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Yi-Sheng ChouSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.ORCID 0000-0001-9572-6936
Chun-Chieh WangDivision of Chest Medicine, Department of Internal Medicine, Puli branch of Taichung Veterans General Hospital, Taichung, Taiwan.
Li-Fei HsuCollege of Public Health, National Taiwan University, Taipei, Taiwan.
Pei-Hung ChuangTaipei Association of Health and Welfare Data Science, Taipei, Taiwan.
Chi-Feng ChengDepartment of Hematology and Oncology, Taipei City Hospital, Renai Branch, Taipei, Taiwan.
Nai-Hsin LiDepartment of General Surgery, Taipei City Hospital, Renai Branch, Taipei, Taiwan.
Chu-Chieh ChenDepartment of Health Care Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
Chien-Liang ChenDepartment of Economics, National Chi Nan University, Nantou, Taiwan.
Yun-Ju LaiSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Yung-Feng YenDepartment of Health Care Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.ORCID 0000-0002-4469-4732
National Yang Ming Chiao Tung University · TWNational Taipei University of Nursing and Health Science · TWTaipei City Hospital · TWMinistry of Health and Welfare · TWNational Taiwan University · TWTaichung Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe risk of ischemic heart disease (IHD) due to the impact of gonadotropin-releasing hormone (GnRH) agonists among female patients with breast cancer remains a controversy.

methodsInformation from the Registry for Catastrophic Illness, the National Health Insurance Research Database (NHIRD), and the Death Registry Database in Taiwan were analyzed. Female patients with breast cancer were selected from the Registry for Catastrophic Illness from January 1, 2000, to December 31, 2018. All the breast cancer patients were followed until new-onset IHD diagnosis, death, or December 31, 2018. A Kaplan-Meier survival curve was drawn to show the difference between patients treated with and without GnRH agonists. The Cox regression analysis was used to investigate the effects of GnRH agonists and the incidence of IHD.

resultsA total of 172,850 female patients with breast cancer were recognized with a mean age of 52.6 years. Among them, 6071(3.5%) had received GnRH agonist therapy. Kaplan-Meier survival curves showed a significant difference between patients with and without GnRH therapy (log-rank p < 0.0001). Patients who received GnRH therapy had a significantly decreased risk of developing IHD than those without GnRH therapy (HR = 0.18; 95% CI = 0.14-0.23). After adjusting for age, treatment, and comorbidity, patients who received GnRH therapy still had a significantly lower risk of developing IHD (AHR = 0.5, 95% CI = 0.39-0.64).

conclusionThe study showed that the use of GnRH agonists for breast cancer treatment was significantly associated with a reduced risk of IHD. Further research is required to investigate the possible protective effect of GnRH on IHD.

Indexed as

Breast NeoplasmsMyocardial IschemiaCatastrophic IllnessCohort StudiesFemaleGonadotropin-Releasing HormoneHumansMiddle AgedGonadotropin-Releasing Hormonebreast neoplasmscardiovascular diseasesgonadotropin-releasing hormoneheart disease risk factorsmyocardial ischemia

Identifiers

PMID36305849
PMCPMC10028063
OpenAlexW4307492879

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read15
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.